“…15) CD11c, 25) toll-like receotor-4 (TLR4), 25) CD163, 25) mannose receptor (MR), 25) and β-actin. 26) Primers, which were purchased from Invitrogen (Carlsberg, CA, U.S.A.), were as follows: MCP-1, forward, 5′-CTT CTG GGC CTG CTG TTC A-3′, reverse, 5′-CCA GCC TAC TCA TTG GGA TCA -3′; F4/80, forward, 5′-CTT TGG CTA TGG GCT TCC AGT C-3′, reverse, 5′-GCA AGG AGG ACG AGT TTA TCG TG-3′, CD68, forward, 5′-CTT CCC ACA GGC AGC ACA G-3′, reverse, 5′-AAT GAT GAG AGG CAG CAA GAG G-3′; CD11c, forward, 5′-CTG GAT AGC CTT TCT TCT GCT G-3′, reverse,5′-GCA CAC TGT GTC CGA ACT C-3′; TLR4, forward, 5′-AGA AAT TCC TGC AGT GGG TCA -3′, reverse, 5′-TCT CTA CAG GTG TTG CAC ATG TCA -3′; CD163, forward, 5′-GGG TCA TTC AGA GGC ACA CTG -3′, reverse, 5′-CTG GCT GTC CTG TCA AGG CT-3′; MR, forward, 5′-CGG TGA ACC AAA TAA TTA CCA AAA T-3′, reverse, 5′-GTG GAG CAG GTG TGG GCT -3′; β-actin, forward, 5′-TGG AAT CCT GTG GCA TCC ATG AAA C-3′, reverse, 5′-TAA AAC GCA GCT CAG TAA CAG TCC G-3′. The amplification products obtained by RT-PCR were mixed with 10× Loading Buffer (TaKaRa, Tokyo, Japan) and were electorophoretically separated on 2% agarose gel.…”